FIA
PRTK

FNY Investment Advisers’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

FNY Investment Advisers’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-500
Closed -$2K – 1120
2019
Q3 		$2K Hold
500
– – ﹤0.01% 761
2019
Q2 		$1K Hold
500
– – ﹤0.01% 912
2019
Q1 		$2K Hold
500
– – ﹤0.01% 617
2018
Q4 		$2K Buy
+500
New +$3.8K ﹤0.01% 595

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FNY Investment Advisers's PRTK Position: Q4 2019 in Review

FNY Investment Advisers sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2019, closing a stake of 500 shares — an estimated $2K sold.

FNY Investment Advisers first reported a position in PRTK in Q4 2018 and held it in 4 quarters. The position peaked at $2K in Q3 2019. 93 funds tracked by Wall St. Rank hold PRTK as of Q4 2019.

  • FNY Investment Advisers reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • FNY Investment Advisers sold 500 Paratek Pharmaceuticals, Inc. shares in Q4 2019, an estimated $2K.
  • FNY Investment Advisers first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2018 and held it in 4 quarters.
  • FNY Investment Advisers's Paratek Pharmaceuticals, Inc. position peaked at $2K in Q3 2019.
  • 93 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2019.

Based on FNY Investment Advisers's 13F filing for Q4 2019, filed 10 Jan 2020.